

The "Hit Hard And Hit Earl" Strategy To Treat Chronic Hepatitis C

A Barreiros, J Schlaak, G Gerken, P Galle, H Löhr

Citation

A Barreiros, J Schlaak, G Gerken, P Galle, H Löhr. *The "Hit Hard And Hit Earl" Strategy To Treat Chronic Hepatitis C*. The Internet Journal of Gastroenterology. 2002 Volume 2 Number 2.

Abstract

Daily dosed interferon-alpha may prevent mutations of the hepatitis C virus (HCV) quasi-species and may therefore be more efficient in the treatment of chronic hepatitis C than the conventional therapy regimen given three times a week (1,2). The drop of viral load in the initial therapy phase has been shown to substantially influence the sustained response rates (3,4). In this randomised case controlled study seventy therapy-naïve patients with chronic hepatitis C were analysed before, during and after IFN treatment. Group A comprised 42 patients, 24 with genotypes 1 or 4 and 18 with genotypes 2 or 3, that received an induction monotherapy with 6 MIU interferon alfa-2a daily s.c. for 12 weeks.

After interferon dosages were tapered down to 4.5 MIU and 3 MIU daily for 4 weeks each, HCV-RNA negative patients received maintenance therapy containing 3 MIU interferon alfa-2a three times weekly plus 800 mg ribavirin p.o. daily for another seven months. Group B comprised 28 patients, 22 with genotype 1 and 6 with genotypes 2 or 3, that had been treated with 6 miu interferon alfa-2a three times weekly for 12 weeks. Then, patients with negative HCV-RNA received the same maintenance combination therapy as described above. Informed written consent was obtained from each subject before treatment. Furthermore, the study protocol was been approved by the local ethics committee.

RESULTS

In group A, biochemical and virological responses were observed in 28 patients (57%) after 12 weeks and 16 patients (38%) at the end of treatment. Six months after therapy 13 patients (31%) showed sustained complete therapy responses defined by viral clearance and normal alanine aminotransferase (ALT) levels. In group B, nine patients (32%) had negative HCV-PCR after 12 weeks and five patients (18%) at the end-of-treatment. However, sustained complete responses were observed only in three patients


(11%) from group B ($p < 0.01$).

Regarding the unfavourable genotype 1 or 4 expression 12 of 24 patients (50%) in group A and five of 22 patients (23%) in group B had negative HCV-RNA after 12 weeks and seven (29%) respectively three patients (14%) at the end of treatment. Six months later, six genotype 1 patients from group A (25%) but only two patients from group B (9%) showed sustained complete responses ($p < 0.01$).

The HCV genotypes 2 or 3 were expressed from 18 patients in group A and six patients in group B. Sixteen patients of group A (89%) and three patients of group B (50%) had negative HCV-RNA after 12 weeks while nine (50%) of group A patients and two (33%) of group B patients showed an end-of-treatment response. Long-term sustained responses were observed in seven patients of group A (39%) but only one patient in group B (17%; $p < 0.01$).

Figure 1

Figure 1: Relative viral clearance rates after 0, 12, 24 and 48 weeks (0, 12w, 24w, 48w) of antiviral therapy and six months after treatment (6 mo post). Induction therapy: Interferon alfa-2a (IFN) 6 miu s.c. daily for 12 weeks, 4,5 miu daily for 4 weeks, 3 miu daily for 4 weeks followed by 3 miu three times weekly (tiw) combined with 800 mg ribavirin daily for 7 months. Conventional therapy: IFN 6 miu tiw for 12 weeks followed by 3 miu tiw plus ribavirin 800 mg daily for 9 months.



DISCUSSION

This intention-to-treat analysis of 70 therapy-naïve patients with chronic hepatitis demonstrated that patients with high dose daily interferon induction therapy (group A) showed significantly higher initial response rates than the patients who received the conventional interferon therapy three times weekly (group B). This effect was also observed when patients with genotypes 1 or 4 and patients with genotypes 2 or 3 were analysed separately (_{5,6}). Similar rates of breakthroughs were observed in during the maintenance therapy with interferon-alfa plus ribavirin in both therapy arms. Therefore, it appeared that the significantly increased end-of-treatment and sustained response rates response observed in group A, were consequent to stronger viral suppression in the initial induction therapy phase (_{2,7}). Although we observed more dose-related adverse effects in group A than in group B, the induction therapy regimen was well tolerated in the majority of patients and WHO grade III or IV severe adverse effects have not been observed at all.

CONCLUSION

We concluded that the high dose induction therapy with daily interferon alfa-2a significantly increased the response rates in this prospective intention-to-treat analysis. Future studies will show whether the prolongation of the initial daily dose regimen, as it might be mimicked by the pharmacokinetic characteristics of the 40kD pegylated interferon alfa-2a formulation, will decrease the relapse rates during maintenance therapy or after therapy cessation.

CORRESPONDENCE TO

Hanns F. Löhr, Prof. Dr. I. Department of Internal Medicine
University Mainz Langenbeckstrasse 1 55131 Mainz,
Germany Tel. +49-6131-17-2380 Fax +49-6131-17-6621 e-
mail loehr@mail.uni-mainz.de

References

1. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. *J Viral Hepat* 2001; 8: 1-18.
2. Layden TJ. Principles of interferon induction therapy. *Am J Med* 1999; 107: 71S-3S.
3. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. *Hepatology* 1997; 26: 226-31.
4. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. *Gastroenterology* 2001; 120: 1438-47.
5. Keeffe EB, Dusheiko GM, James SP, et al. Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group. *Cytokines Cell Mol Ther* 1999; 5: 207-10.
6. Fernandez I, Castellano G, Domingo MJ, et al. Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection. *Scand J Gastroenterol* 1997; 32: 70-6.
7. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. *J Hepatol* 1995; 23: 487-96.

Author Information

Ana Paula Barreiros, MD

I. Department of Internal Medicine, Johannes Gutenberg-University

Jörg Schlaak, MD

Department of Gastroenterology and Hepatology, University Essen

Guido Gerken, PhD.

Department of Gastroenterology and Hepatology, University Essen

PR Galle, PhD

I. Department of Internal Medicine, Johannes Gutenberg-University

Hanns Löhr, PhD.

I. Department of Internal Medicine, Johannes Gutenberg-University